The cytoplasmic expression of MUC1 in papillary thyroid carcinoma of different histological variants and its correlation with cyclin D1 overexpression

Endocrine Pathology

Volumn 18, Issue 2, 2007, Pages 68-75

  Abrosimov, Alexander ^a,b   Saenko, Vladimir ^a,b   Meirmanov, Serik ^a   Nakashima, Masahiro ^a   Rogounovitch, Tatiana ^a   Shkurko, Olesya ^b   Lushnikov, Eugeny ^b   Mitsutake, Norisato ^a   Namba, Hiroyuki ^a   Yamashita, Shunichi ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

Author keywords

Cyclin D1; Histotype; MUC1; Papillary thyroid carcinoma

Indexed keywords

CYCLIN D1; MUCIN 1;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; THYROID CARCINOMA;

ADULT; CA-15-3 ANTIGEN; CARCINOMA, PAPILLARY; CYCLIN D1; CYTOPLASM; FEMALE; GENETIC MARKERS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PARAFFIN EMBEDDING; PROGNOSIS; THYROID NEOPLASMS;

EID: 35348894341     PISSN: 10463976     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12022-007-0012-x     Document Type: Article

References (31)

1. Gendler SJ. MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia 6:339-53, 2001.
2. Perez-Vilar J, Hill RL. The structure and assembly of secreted mucins. J Biol Chem 274:31751-4, 1999.
3. Alves P, Soares P, Fonseca E, et al. Papillary thyroid carcinoma overexpresses fully and underglycosylated mucins together with native and sialylated simple mucin antigens and histo-blood group antigens. Endocr Pathol 10:315-24, 1999.
4. Magro G, Schiappacassi M, Perissinotto D, et al. Differential expression of mucins 1-6 in papillary thyroid carcinoma: evidence for transformation- dependent post-translational modifications of MUC1 in situ. J Pathol 200:357-69, 2003.
5. Weiss M, Baruch A, Keydar I, et al. Preoperative diagnosis of thyroid papillary carcinoma by reverse transcriptase polymerase chain reaction of the MUC1 gene. Int J Cancer 66:55-9, 1996.
6. Bieche I, Ruffet E, Zweibaum A, et al. MUC1 mucin gene, transcripts, and protein in adenomas and papillary carcinomas of the thyroid. Thyroid 7:725-31, 1997.
7. Wreesmann VB, Sieczka EM, Socci ND, et al. Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker. Cancer Res 64:3780-9, 2004.
8. Patel KN, Maghami E, Wreesmann VB, et al. MUC1 plays a role in tumor maintenance in aggressive thyroid carcinomas. Surgery 138:994-1001; discussion 1001-2, 2005.
9. Carraway KL, Ramsauer VP, Haq B, et al. Cell signaling through membrane mucins. Bioessays 25:66-71, 2003.
10. Schroeder JA, Adriance MC, Thompson MC, et al. MUC1 alters beta-catenin-dependent tumor formation and promotes cellular invasion. Oncogene 22:1324-32, 2003.
11. Wen Y, Caffrey TC, Wheelock MJ, et al. Nuclear association of the cytoplasmic tail of MUC1 and beta-catenin. J Biol Chem 278:38029-39, 2003.
12. Wesseling J, van der Valk SW, Vos HL, et al. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol 129:255-65, 1995.
13. Hatsell S, Rowlands T, Hiremath M, et al. Beta-catenin and Tcfs in mammary development and cancer. J Mammary Gland Biol Neoplasia 8:145-58, 2003.
14. Cadigan KM, Nusse R. Wnt signaling: a common theme in animal development. Genes Dev 11:3286-305, 1997.
15. Gumbiner BM. Signal transduction of beta-catenin. Curr Opin Cell Biol 7:634-40, 1995.
16. Ishigaki K, Namba H, Nakashima M, et al. Aberrant localization of beta-catenin correlates with overexpression of its target gene in human papillary thyroid cancer. J Clin Endocrinol Metab 87:3433-40, 2002.
17. Nakashima M, Meirmanov S, Naruke Y, et al. Cyclin D1 overexpression in thyroid tumours from a radio-contaminated area and its correlation with Pin1 and aberrant beta-catenin expression. J Pathol 202:446-55, 2004.
18. Lantsov D, Meirmanov S, Nakashima M, et al. Cyclin D1 overexpression in thyroid papillary microcarcinoma: its association with tumour size and aberrant beta-catenin expression. Histopathology 47:248-56, 2005.
19. LiVolsi V. Surgical pathology of the thyroid. Philadelphia: Saunders; 1990.
20. Rosai J, Carciangiu ML, DeLellis RA. Tumors of the thyroid gland. Washington, D.C.: Armed Forces Institute of Pathology; 1992.
21. LiVolsi VA, Albores-Saavedra J, Asa SL. Papillary carcinoma. In: DeLellis RA, Lloyd R, Hertz PhU, Eng C, editors. WHO classification of tumors. Pathology and genetics of tumors of endocrine organs. Lyon: IARC Press. p. 57-66, 2004.
22. Khoo ML, Ezzat S, Freeman JL, et al. Cyclin D1 protein expression predicts metastatic behavior in thyroid papillary microcarcinomas but is not associated with gene amplification. J Clin Endocrinol Metab 87:1810-3, 2002.
23. Hunt JL, LiVolsi VA, Baloch ZW, et al. Microscopic papillary thyroid carcinoma compared with clinical carcinomas by loss of heterozygosity mutational profile. Am J Surg Pathol 27:159-66, 2003.
24. Apel RL, Asa SL, LiVolsi VA. Papillary Hurthle cell carcinoma with lymphocytic stroma. "Warthin-like tumor" of the thyroid. Am J Surg Pathol 19:810-14, 1995.
25. Ozaki O, Ito K, Mimura T, et al. Papillary carcinoma of the thyroid. Tall-cell variant with extensive lymphocyte infiltration. Am J Surg Pathol 20:695-8, 1996.
26. DeGroot LJ, Kaplan EL, McCormick M, et al. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 71:414-24, 1990.
27. Rahn JJ, Dabbagh L, Pasdar M, et al. The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature. Cancer 91:1973-82, 2001.
28. Giordano TJ, Kuick R, Thomas DG, et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 24:6646-56, 2005.
29. Castro P, Rebocho AP, Soares RJ, et al. PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab 91:213-20, 2006.
30. Zhu Z, Gandhi M, Nikiforova MN, et al. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol 120:71-7, 2003.
31. Shaha AR, Shah JP, Loree TR. Patterns of failure in differentiated carcinoma of the thyroid based on risk groups. Head Neck 20:26-30, 1998.